Evidence mapPaperPMID 38959429Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

HbA

Chris Moran, Rachel A Whitmer, Zoe Dove, Mary E Lacy, Yenee Soh, Ai-Lin Tsai, Charles P Quesenberry, Andrew J Karter, Alyce S Adams, Paola Gilsanz

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. HbAAlzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chris MoranSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.ORCID 0000-0003-1872-3314
Rachel A WhitmerDivision of Epidemiology, Department of Public Health Sciences, University of California, Medical Sciences 1-C, Davis, California, USA.
Zoe DoveKaiser Permanente Division of Research, Oakland, California, USA.
Mary E LacyKaiser Permanente Division of Research, Oakland, California, USA.
Yenee SohKaiser Permanente Division of Research, Oakland, California, USA.
Ai-Lin TsaiKaiser Permanente Division of Research, Oakland, California, USA.
Charles P QuesenberryKaiser Permanente Division of Research, Oakland, California, USA.
Andrew J KarterKaiser Permanente Division of Research, Oakland, California, USA.
Alyce S AdamsKaiser Permanente Division of Research, Oakland, California, USA.
Paola GilsanzKaiser Permanente Division of Research, Oakland, California, USA.

Funding

UC Davis Alzheimer's Disease Research CenterP30AG072972 · UNIVERSITY OF CALIFORNIA AT DAVIS · 2025 to 2025
$3.2M
Glycemic Control and Dementia: The Role of Pharmacotherapy and Vascular ComplicationsR01AG067199 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Paola Gilsanz · 2023 to 2024
$779k
Translational Research Core - Health Engagement & Action Translational (HEAT)P30DK092924 · KAISER FOUNDATION RESEARCH INSTITUTE · 2025 to 2025
$700k
Identifying lifelong factors that impact brain health and outcomes in type 1 diabetes: The Cognition and Longitudinal Assessments of Risk Factors over 30 Years (CLARiFY) Diabetes Complications StudyR01DK129320 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2025 to 2025
$442k
NIA NIH HHS P30 AG072972NIA NIH HHS R01 AG063391NIA NIH HHS R01-AG063391NIA NIH HHS R01 AG067199NIA NIH HHS R01-AG067199NIDDK NIH HHS P30 DK092924NIDDK NIH HHS R01 DK129320NIH HHS R01-DK129320
6 · The paper itself

Abstract

introductionAlthough poor glycemic control is associated with dementia, it is unknown if variability in glycemic control, even in those with optimal glycosylated hemoglobin A

methodsAmong 171,964 people with type 2 diabetes, we evaluated the hazard of dementia association with long-term HbA

resultsThe mean baseline age was 61 years (48% women). Greater HbA DISCUSSION: Greater HbA HIGHLIGHTS: We observed a cohort of 171,964 people with type 2 diabetes (mean age 61 years). This cohort was based in Northern California between 1996 and 2018. We examined the association between glycosylated hemoglobin A

Indexed as

DementiaDiabetes Mellitus, Type 2Glycated HemoglobinAgedBlood GlucoseFemaleHumansMaleMiddle AgedRisk FactorsBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humandementiadiabetesglycemic controlglycosylated hemoglobin A1c variability

Identifiers

PMID38959429
PMCPMC11350038

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.